Intellia Therapeutics is downgraded to Sell due to safety concerns and weak commercial prospects in ATTR and HAE. NTLA's ATTR program faces a clinical hold after a Hy’s-law-threshold liver event, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback